Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
The Phase 2 extension study evaluates the long-term efficacy and safety of iptacopan treatment in participants with C3 glomerulopathy (C3G), an ultra-rare disease. Here we report the 39-month follow-up data.
Adults with native (Cohort [Co] A) or recurrent C3G post-kidney transplant (CoB) received iptacopan 200 mg twice-daily (bid) for at least 12 weeks in the Phase 2 study before entering the open-label extension study (NCT03955445). Long-term efficacy was assessed by several renal endpoints (e.g., proteinuria, estimated glomerular filtration rate [eGFR]). Safety and tolerability of iptacopan was continually monitored.
Of 27 participants completing the 12-week Phase 2 study, 26 (16 CoA, 10 CoB) entered the extension study for treatment with iptacopan 200 mg bid; 21 participants (13 CoA, 8 CoB) completed 39-month follow-up (3 months Phase 2 plus 36 months extension). In CoA, there was a sustained reduction in proteinuria (first morning void [FMV] urine protein–creatinine ratio [UPCR]) over time with a reduction of 40% from baseline at 39 months. Compared to the pre-treatment eGFR slope of -13.4 mL/min/1.73m2/year, the annualized eGFR slope was -2.1 mL/min/1.73m2/year at 39 months (CoA) representing an improvement of +11.4 mL/min/1.73m2/year (p=0.0089) following initiation of iptacopan. In CoB, proteinuria levels (FMV UPCR) were mostly normal at baseline and remained well controlled (<0.4 g/g in the 7 participants with data at 39 months) over the study period up to 39 months. The mean change in eGFR from baseline was -5.8 mL/min/1.73m2 at 39 months in CoB. 6 of 8 participants (75.0%; 95% CI: 40.9, 92.9) had a stable or improved eGFR (defined as ≤10% reduction in eGFR compared to baseline), and 2 participants had an eGFR decline of >10%. Iptacopan was generally well-tolerated with safety consistent with iptacopan’s known profile.
Long-term iptacopan therapy is associated with a sustained and clinically relevant reduction in proteinuria and an improved eGFR slope in native C3G. A stable eGFR was maintained in a majority of participants with recurrent C3G. Iptacopan was well tolerated with a favorable safety profile in both cohorts.
This abstract was also submitted to the American Society of Nephrology (ASN) Kidney Week 2025 Congress, November 6–9, in Houston, TX, USA. Encore submission of this abstract to WCN 2026 is permitted by the organizers of the original meeting (ASN 2025).
